Catalent chief John Chiminski triggers a $315M-plus wager on the booming cell therapy market now in the making
Last year Catalent CEO John Chiminski invested more than a billion dollars to expand the contract manufacturer ahead of an explosion of gene therapy trials and expected approvals. He’s starting this year with a $315 million wager on the booming cell therapy field.
Just ahead of the market open Monday, Chiminski $CTLT laid out to me the details of his decision to buy a transatlantic player that has been building up manufacturing capability in CAR-Ts, TCRs, TILs (tumor-infiltrating lymphocytes) and mesenchymal stem cell therapies.
In exchange for the $315 million in cash, he’s getting MaSTherCell Global and its 32,000 square-foot facility in Houston and a 25,000 square-foot facility in Gosselies, Belgium. The manufacturing operation is in the process of building out a 60,000-square-foot addition in Belgium set to go live next year, expanding beyond clinical supplies to the commercial realm.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.